Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled multicenter study of pirfenidone capsules in pneumoconiosis
CTR20220369Phase 3Active
- Sponsor
- Gyre Pharmaceuticals
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pirfenidone in pneumoconiosis, silicosis, coal workers' pneumoconiosis (CWP), sponsored by Gyre Pharmaceuticals. Started Jun 2022; status: active.
02
Drugs
pirfenidone
03
Conditions
pneumoconiosissilicosiscoal workers' pneumoconiosis (CWP)
Beyond the preview
Go deeper on CTR20220369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220369.